argenx SE
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
Registration date
11 aug 2022 - 13:07
Statutory name
argenx SE
Title
argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis
Date last update: 11 October 2026